X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It is under phase 3 clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Through the acquisition, LEO expand its pipeline by including TMB-001, an investigational topical reformulation of the active pharmaceutical ingredient, isotretinoin that today only exists in an oral formulation in the U.S.
Lead Product(s): Isotretinoin
Therapeutic Area: Dermatology Product Name: TMB-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Timber Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2024
Details:
Adbry (tralokinumab-ldrm) is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis signs and symptoms.
Lead Product(s): Tralokinumab-ldrm
Therapeutic Area: Dermatology Product Name: Adbry
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
LEO 138559 (temtokibart) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Temtokibart
Therapeutic Area: Dermatology Product Name: LEO 138559
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Through the acquisition, LEO gains rights to establish TMB-001, topical isotretinoin in Timber's patented IPEG™ delivery system, as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.
Lead Product(s): Isotretinoin
Therapeutic Area: Genetic Disease Product Name: TMB-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Timber Pharmaceuticals
Deal Size: $36.0 million Upfront Cash: $14.0 million
Deal Type: Acquisition August 21, 2023
Details:
Adtralza (tralokinumab), is a pre-filled pen Injection Device with high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis and symptoms.
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: Adtralza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
LEO 138559 is an investigational monoclonal antibody which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine, it is currently being developed for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): LEO 138559
Therapeutic Area: Dermatology Product Name: LEO 138559
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
Adtralza (tralokinumab), is the first and only approved human, monoclonal antibody developed to specifically target and neutralize the IL-13 cytokine, which plays a key role in immune and inflammatory process which are the underlying causes of atopic dermatitis.
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: Adtralza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
